Esperion Therapeutics' aggressive commercialization efforts have significantly boosted retail prescriptions and broadened ...

Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Thank you for standing by and welcome to Heron Therapeutics ...

Axsome Therapeutics surpassed revenue expectations in Q3, driven by strong sales from its key products.

Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on AXSM stock, giving a Buy rating on November 8. Graig ...

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Regulus (RGLS – Research Report) and keeping the price target at ...

Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Ladies and gentlemen, thank you for standing by. At this time, all participants are in a listen-only mode. After the speakers’ presentation ...

Sangamo Therapeutics ranks at the bottom for Revenue Growth and Gross Profit, indicating lower performance compared to its peers. However, it ranks in the middle for Return on Equity, suggesting ...

As per Deloitte, inflation in the Eurozone slightly rebounded in October but was still quite low. The consumer price index ...

TG Therapeutics' Q3 earnings missed EPS expectations despite Briumvi's revenue growth. See why TGTX stock is a Buy.

During the third quarter, TG Therapeutics boosted Briumvi's market penetration, driving U.S. net revenue up by over 230% year ...

UTHR boasts an average earnings surprise of 4.2%. United Therapeutics is also cash rich. The company has generated cash flow growth of 10.7%, and is expected to report cash flow expansion of 33.3% ...

Analysts anticipate Halozyme Therapeutics to report an earnings per share (EPS) of $0.98. Investors in Halozyme Therapeutics ...